Nukkleus Total Liab vs Total Current Assets Analysis

NUKK Stock

USD 1.52 0.01 0.65%

Nukkleus financial indicator trend analysis is infinitely more than just investigating Nukkleus recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Nukkleus is a good investment. Please check the relationship between Nukkleus Total Liab and its Total Current Assets accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Nukkleus. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in industry.

For more information on how to buy Nukkleus Stock please use our How to buy in Nukkleus Stock guide.

Total Liab vs Total Current Assets

Total Liab vs Total Current Assets Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Nukkleus Total Liab account and Total Current Assets. At this time, the significance of the direction appears to have almost identical trend.

The correlation between Nukkleus' Total Liab and Total Current Assets is 0.97. Overlapping area represents the amount of variation of Total Liab that can explain the historical movement of Total Current Assets in the same time period over historical financial statements of Nukkleus, assuming nothing else is changed. The correlation between historical values of Nukkleus' Total Liab and Total Current Assets is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Liab of Nukkleus are associated (or correlated) with its Total Current Assets. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Current Assets has no effect on the direction of Total Liab i.e., Nukkleus' Total Liab and Total Current Assets go up and down completely randomly.

Correlation Coefficient

0.97

Relationship Direction	Positive
Relationship Strength	Very Strong

View All Relationships

Total Liab

The total amount of all liabilities that a company has, including both short-term and long-term liabilities.

Total Current Assets

The total value of all assets that are expected to be converted into cash within one year or during the normal operating cycle.

Most indicators from Nukkleus' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Nukkleus current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Nukkleus. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in industry.

For more information on how to buy Nukkleus Stock please use our How to buy in Nukkleus Stock guide.Selling General Administrative is expected to rise to about 3.4 M this year, although the value of Sales General And Administrative To Revenue will most likely fall to 0.19.

	2021	2022	2023	2024 (projected)
Total Operating Expenses	28.3M	3.2M	3.7M	3.5M
Cost Of Revenue	22.2M	16.3M	18.7M	14.8M

Total Operating Expenses Cost Of Revenue

Nukkleus fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Cash	Cash And Short Term Investments	Common Stock Shares Outstanding	Other Stockholder Equity	Total Liab	Total Current Assets	Common Stock	Net Tangible Assets	Long Term Debt	Net Receivables	Non Current Liabilities Total	Other Current Assets	Short Long Term Debt Total	Net Invested Capital	Net Working Capital	Capital Stock	Current Deferred Revenue
Total Assets		0.89	0.95	0.98	-0.36	-0.91	0.98	0.94	0.91	-0.28	0.86	0.95	0.9	0.01	0.75	0.05	0.39	-0.08	0.88	0.92	0.99	-0.92	0.93	0.84
Other Current Liab	0.89		0.94	0.82	-0.39	-0.8	0.83	0.83	0.82	-0.63	0.92	0.93	0.92	-0.15	0.64	0.06	0.6	-0.01	0.91	0.79	0.83	-0.86	0.78	0.73
Total Current Liabilities	0.95	0.94		0.88	-0.47	-0.92	0.89	0.89	0.88	-0.41	0.81	1.0	0.97	0.02	0.73	0.04	0.51	-0.08	0.95	0.86	0.89	-0.96	0.86	0.84
Total Stockholder Equity	0.98	0.82	0.88		-0.3	-0.87	0.99	0.93	0.89	-0.2	0.84	0.87	0.82	-0.02	0.73	0.0	0.31	-0.13	0.79	0.91	1.0	-0.86	0.92	0.8
Net Debt	-0.36	-0.39	-0.47	-0.3		0.59	-0.36	-0.4	-0.41	0.41	-0.36	-0.43	-0.3	0.52	-0.67	0.42	0.12	0.46	-0.3	-0.51	-0.3	0.52	-0.38	-0.61
Retained Earnings	-0.91	-0.8	-0.92	-0.87	0.59		-0.87	-0.85	-0.84	0.28	-0.76	-0.92	-0.82	0.07	-0.9	-0.03	-0.15	0.1	-0.8	-0.94	-0.87	0.94	-0.89	-0.96
Accounts Payable	0.98	0.83	0.89	0.99	-0.36	-0.87		0.92	0.88	-0.22	0.84	0.87	0.82	-0.05	0.74	-0.04	0.32	-0.17	0.79	0.91	0.99	-0.86	0.92	0.81
Cash	0.94	0.83	0.89	0.93	-0.4	-0.85	0.92		0.97	-0.2	0.81	0.88	0.83	0.07	0.68	0.02	0.35	-0.1	0.79	0.83	0.93	-0.89	0.87	0.78
Cash And Short Term Investments	0.91	0.82	0.88	0.89	-0.41	-0.84	0.88	0.97		-0.16	0.79	0.87	0.79	0.12	0.63	0.02	0.31	-0.11	0.75	0.78	0.9	-0.92	0.85	0.76
Common Stock Shares Outstanding	-0.28	-0.63	-0.41	-0.2	0.41	0.28	-0.22	-0.2	-0.16		-0.61	-0.39	-0.4	0.68	-0.36	0.18	-0.42	0.09	-0.42	-0.33	-0.2	0.28	-0.2	-0.29
Other Stockholder Equity	0.86	0.92	0.81	0.84	-0.36	-0.76	0.84	0.81	0.79	-0.61		0.8	0.74	-0.35	0.7	0.03	0.34	0.0	0.72	0.83	0.85	-0.74	0.77	0.71
Total Liab	0.95	0.93	1.0	0.87	-0.43	-0.92	0.87	0.88	0.87	-0.39	0.8		0.97	0.06	0.72	0.14	0.5	0.01	0.96	0.86	0.88	-0.96	0.86	0.84
Total Current Assets	0.9	0.92	0.97	0.82	-0.3	-0.82	0.82	0.83	0.79	-0.4	0.74	0.97		0.13	0.6	0.2	0.65	0.08	1.0	0.77	0.82	-0.89	0.79	0.74
Common Stock	0.01	-0.15	0.02	-0.02	0.52	0.07	-0.05	0.07	0.12	0.68	-0.35	0.06	0.13		-0.38	0.42	0.23	0.31	0.12	-0.23	0.0	-0.09	0.0	-0.15
Net Tangible Assets	0.75	0.64	0.73	0.73	-0.67	-0.9	0.74	0.68	0.63	-0.36	0.7	0.72	0.6	-0.38		-0.02	-0.14	-0.12	0.59	0.94	0.73	-0.71	0.74	0.9
Long Term Debt	0.05	0.06	0.04	0.0	0.42	-0.03	-0.04	0.02	0.02	0.18	0.03	0.14	0.2	0.42	-0.02		0.0	0.98	0.2	0.03	0.01	0.01	-0.03	-0.01
Net Receivables	0.39	0.6	0.51	0.31	0.12	-0.15	0.32	0.35	0.31	-0.42	0.34	0.5	0.65	0.23	-0.14	0.0		-0.01	0.66	0.09	0.32	-0.39	0.27	0.07
Non Current Liabilities Total	-0.08	-0.01	-0.08	-0.13	0.46	0.1	-0.17	-0.1	-0.11	0.09	0.0	0.01	0.08	0.31	-0.12	0.98	-0.01		0.09	-0.09	-0.12	0.14	-0.13	-0.12
Other Current Assets	0.88	0.91	0.95	0.79	-0.3	-0.8	0.79	0.79	0.75	-0.42	0.72	0.96	1.0	0.12	0.59	0.2	0.66	0.09		0.75	0.8	-0.87	0.77	0.72
Short Long Term Debt Total	0.92	0.79	0.86	0.91	-0.51	-0.94	0.91	0.83	0.78	-0.33	0.83	0.86	0.77	-0.23	0.94	0.03	0.09	-0.09	0.75		0.91	-0.83	0.88	0.91
Net Invested Capital	0.99	0.83	0.89	1.0	-0.3	-0.87	0.99	0.93	0.9	-0.2	0.85	0.88	0.82	0.0	0.73	0.01	0.32	-0.12	0.8	0.91		-0.86	0.92	0.8
Net Working Capital	-0.92	-0.86	-0.96	-0.86	0.52	0.94	-0.86	-0.89	-0.92	0.28	-0.74	-0.96	-0.89	-0.09	-0.71	0.01	-0.39	0.14	-0.87	-0.83	-0.86		-0.88	-0.87
Capital Stock	0.93	0.78	0.86	0.92	-0.38	-0.89	0.92	0.87	0.85	-0.2	0.77	0.86	0.79	0.0	0.74	-0.03	0.27	-0.13	0.77	0.88	0.92	-0.88		0.92
Current Deferred Revenue	0.84	0.73	0.84	0.8	-0.61	-0.96	0.81	0.78	0.76	-0.29	0.71	0.84	0.74	-0.15	0.9	-0.01	0.07	-0.12	0.72	0.91	0.8	-0.87	0.92

Click cells to compare fundamentals

Nukkleus Account Relationship Matchups

Nukkleus fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	203.0K	3.8M	16.7M	18.4M	21.1M	22.2M
Other Current Liab	5.0M	4.6M	2.5M	7.2M	8.3M	8.7M
Total Current Liabilities	1.3M	5.2M	4.6M	7.5M	8.6M	9.0M
Total Stockholder Equity	(1.3M)	(1.4M)	12.0M	10.9M	12.5M	13.2M
Net Debt	158.3K	161.0K	1.3M	(364.0K)	(418.6K)	(397.7K)
Retained Earnings	(1.5M)	(1.6M)	(2.5M)	(14.3M)	(12.9M)	(12.3M)
Cash	23.5K	82.8K	355.7K	364.0K	418.6K	439.6K
Cash And Short Term Investments	192.5K	82.9K	355.7K	364.0K	418.6K	439.6K
Common Stock Shares Outstanding	6.3M	257.8M	367.2M	10.1M	9.1M	8.6M
Liabilities And Stockholders Equity	203.0K	3.8M	16.7M	18.4M	21.1M	22.2M
Total Liab	1.5M	5.2M	4.6M	7.5M	8.6M	9.0M
Total Current Assets	203.0K	3.8M	3.0M	3.7M	4.2M	4.5M
Net Tangible Assets	(1.3M)	(1.4M)	(1.6M)	2.8M	3.2M	3.4M
Net Receivables	3.7M	2.7M	35K	966.1K	1.1M	1.0M
Short Term Investments	168.9K	12.0	1.2M	248.2K	285.4K	224.1K
Non Current Liabilities Total	246.2K	247.6K	180.5K	254.9K	229.4K	285.1K
Inventory	(172.8K)	(3.7M)	(2.6M)	2.0M	1.8M	1.9M
Other Current Assets	3.7M	2.6M	3.3M	3.3M	3.8M	4.0M
Short Term Debt	181.8K	243.8K	49.0K	3.7M	4.2M	4.4M
Short Long Term Debt Total	181.8K	243.8K	1.6M	3.7M	4.2M	4.4M
Net Invested Capital	(1.3M)	(1.4M)	12.0M	10.9M	12.5M	13.2M
Net Working Capital	(1.0M)	(1.4M)	(1.6M)	(3.8M)	(3.4M)	(3.2M)

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether Nukkleus is a strong investment it is important to analyze Nukkleus' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Nukkleus' future performance. For an informed investment choice regarding Nukkleus Stock, refer to the following important reports:

How To Invest In Nukkleus

Details

Is Nukkleus Stock a good investment?

Details

What is Nukkleus' Net Worth?

Details

Largest Application Software Companies

View

Largest Software - Application Companies

View

Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Nukkleus. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in industry.

For more information on how to buy Nukkleus Stock please use our How to buy in Nukkleus Stock guide.

You can also try the Stocks Directory module to find actively traded stocks across global markets.

Is Application Software space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Nukkleus. If investors know Nukkleus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Nukkleus listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(19.36)

Revenue Per Share

7.024

Quarterly Revenue Growth

(0.97)

Return On Assets

(1.15)

Return On Equity

(7.42)

The market value of Nukkleus is measured differently than its book value, which is the value of Nukkleus that is recorded on the company's balance sheet. Investors also form their own opinion of Nukkleus' value that differs from its market value or its book value, called intrinsic value, which is Nukkleus' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Nukkleus' market value can be influenced by many factors that don't directly affect Nukkleus' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Nukkleus' value and its price as these two are different measures arrived at by different means. Investors typically determine if Nukkleus is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Nukkleus' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Nukkleus Total Liab vs Total Current Assets Analysis

Total Liab vs Total Current Assets

Total Liab vs Total Current Assets Correlation Analysis

Correlation Coefficient

Total Liab

Total Current Assets

Nukkleus fundamental ratios Correlations

Nukkleus Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Nukkleus fundamental ratios Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Liab	+ 1.0	Total Current Liabilities
Net Invested Capital	+ 1.0	Total Stockholder Equity
Other Current Assets	+ 1.0	Total Current Assets
Net Invested Capital	+ 0.99	Total Assets
Accounts Payable	+ 0.99	Total Stockholder Equity
Net Invested Capital	+ 0.99	Accounts Payable

Net Working Capital	- 0.96	Total Liab
Current Deferred Revenue	- 0.96	Retained Earnings
Net Working Capital	- 0.96	Total Current Liabilities
Short Long Term Debt Total	- 0.94	Retained Earnings
Net Working Capital	- 0.92	Cash And Short Term Investments
Total Liab	- 0.92	Retained Earnings